Objective This study evaluated the characteristics of new users of sodium glucose co-transporter 2 inhibitors (SGLT2i) in clinical practice to assess the applicability of the findings from clinical trials (Empagliflozin. Cardiovascular Outcomes and Mortality in Type 2 Diabetes (EMPA-REG OUTCOME) trial. Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 trial. Canagliflozi... https://www.ealisboa.com/super-find-2009-2014-Dodge-Ram-1500-4pc-Bolt-on-Rivet-Style-Spyder-Fender-Flares-hot-value/